Varicella-Zoster Virus Prophylaxis with Low-Dose Acyclovir in Patients with Multiple Myeloma Treated with Bortezomib
| Autor: | Lucie Burešová, Krivanová A, Tomas Buchler, Zdenek Adam, Lenka Zahradová, Jiri Vorlicek, Roman Hájek, Ludek Pour, Viera Sandecká, Marta Krejčí |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Herpesvirus 3 Human Cancer Research medicine.medical_specialty viruses Acyclovir Antineoplastic Agents medicine.disease_cause Antiviral Agents Herpes Zoster Gastroenterology Virus Bortezomib 03 medical and health sciences 0302 clinical medicine immune system diseases hemic and lymphatic diseases Internal medicine Humans Medicine In patient Prospective Studies Prospective cohort study Multiple myeloma Aged Aged 80 and over integumentary system business.industry Low dose Varicella zoster virus virus diseases Hematology General Medicine Middle Aged medicine.disease Boronic Acids 3. Good health Oncology Pyrazines 030220 oncology & carcinogenesis Immunology Female Virus Activation Multiple Myeloma Complication business 030215 immunology medicine.drug |
| Zdroj: | Clinical Lymphoma and Myeloma. 9:151-153 |
| ISSN: | 1557-9190 |
| DOI: | 10.3816/clm.2009.n.036 |
| Popis: | Varicella-zoster virus (VZV) reactivation is a common complication in patients with multiple myeloma (MM) treated with bortezomib, with an incidence rate of 10%-60%. The aim of our study was to analyze the effect of acyclovir prophylaxis in this patient population.We studied 98 consecutive patients with relapsed MM treated with bortezomib. Bortezomib 1.3 mg/m2 was given on days 1, 4, 8, and 11 of a 21-day cycle. At first, patients did not receive any VZV prophylaxis, but because of the high incidence of VZV reactivation, VZV prophylaxis with acyclovir was implemented subsequently.A total of 11 patients treated with bortezomib did not have any VZV prophylaxis, and 4 of these 11 patients (36%) developed VZV reactivation in the form of herpes zoster. No VZV reactivations were observed in the 32 patients who received acyclovir 400 mg 3 times daily or the 55 patients who received acyclovir in a dose reduced to 400 mg once daily during bortezomib treatment.Varicellazoster virus reactivation is a common and serious adverse effect of bortezomib treatment. Acyclovir 400 mg once daily is sufficient to protect from VZV reactivation in patients with MM treated with bortezomib. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect